CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer

Phase 3IMNN-001Positive
AI Analysis

Summary

IMUNON reports strong enrollment momentum in its Phase 3 OVATION 3 trial of IMNN-001 for advanced ovarian cancer treatment.

Clinical Trial Data

Phase

Phase 3

Importance:5/10
Sentiment:
0.50
Phase 3Ovarian CancerEnrollmentIMNN-001
Related Companies

Read the original article

Published by yahoo_finance on July 30, 2026 1:00 PM

Read Original